These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 2905033)

  • 1. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
    Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
    Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
    Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
    Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
    Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM
    J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-erbB-2 amplification in node-negative human breast cancer.
    Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
    Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer.
    King CR; Swain SM; Porter L; Steinberg SM; Lippman ME; Gelmann EP
    Cancer Res; 1989 Aug; 49(15):4185-91. PubMed ID: 2568168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
    Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP
    Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma.
    Weidner U; Peter S; Strohmeyer T; Hussnätter R; Ackermann R; Sies H
    Cancer Res; 1990 Aug; 50(15):4504-9. PubMed ID: 1973362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
    Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
    Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
    Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
    Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas.
    Park JB; Rhim JS; Park SC; Kimm SW; Kraus MH
    Cancer Res; 1989 Dec; 49(23):6605-9. PubMed ID: 2573419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogene patterns in breast and ovarian carcinomas.
    Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
    Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
    van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
    N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
    Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
    Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
    Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
    Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
    Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
    Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.
    Kury FD; Schneeberger C; Sliutz G; Kubista E; Salzer H; Medl M; Leodolter S; Swoboda H; Zeillinger R; Spona J
    Oncogene; 1990 Sep; 5(9):1403-8. PubMed ID: 1699198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.